Thermodynamic stability modulates chaperone-mediated disaggregation of α-synuclein fibrils
- PMID: 41257205
- PMCID: PMC12622358
- DOI: 10.1039/d5sc04927j
Thermodynamic stability modulates chaperone-mediated disaggregation of α-synuclein fibrils
Abstract
Aggregation of the intrinsically disordered protein alpha-synuclein into amyloid fibrils and their subsequent intracellular accumulation are hallmark features of several neurodegenerative disorders, including Parkinson's disease, for which no curative treatments currently exist. In this study, we investigate the relationship between fibril morphology, thermodynamic stability, and susceptibility to disaggregation by the human chaperone system comprising HSP70, DNAJB1, and Apg2. By varying assembly conditions and incubation times, we generated alpha-synuclein fibrils with diverse morphological and biochemical properties, including a broad range of thermodynamic stabilities, which we quantified using a chemical depolymerization assay. The chaperone system effectively disaggregated three of the four fibril types, with efficiencies that correlated with their thermodynamic stabilities. One fibril type resisted disaggregation despite exhibiting a comparable stability to those that were disaggregated, suggesting that additional structural features influence chaperone susceptibility. Our findings establish a quantitative link between fibril stability and chaperone-mediated disaggregation for three in vitro αSyn fibril types as well as fibrils amplified from brain extracts of PD but not MSA patients, highlighting the importance of fibril thermodynamics in biologically relevant disaggregation processes and disease pathology.
This journal is © The Royal Society of Chemistry.
Conflict of interest statement
C. S. is a Founder, Chief Scientific Officer, consultant and shareholder of Amprion Inc., a biotechnology company that focuses on the commercial use of seed amplification assays for high-sensitivity detection of misfolded protein aggregates involved in various neurodegenerative diseases. The University of Texas Health Science Center at Houston has licensed patents and patent applications to Amprion.
Figures
References
-
- Sheppard O. and Coleman M., Alzheimer's Disease: Etiology, Neuropathology and Pathogenesis, in Alzheimer's Disease: Drug Discovery, ed. Huang, X., Exon Publications, 2020, pp. 1–22
-
- Kouli A., Torsney K. M. and Kuan W.-L., Parkinson's Disease: Etiology, Neuropathology, and Pathogenesis. in Parkinson's Disease: Pathogenesis and Clinical Aspects, ed. Stoker, T. B. and Greenland, J. C., Codon Publications, 2018, pp. 3–26
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
